• By Dana Sparks

FDA Warning on Common Blood Pressure Medication

July 10, 2013

Food and Drug Administration (FDA) regulators have issued a warning on the blood pressure drug known generically as olmesartan medoxomil. The drug can cause severe, chronic diarrhea and substantial weight loss, sometimes requiring hospitalization. The FDA says the intestinal problems, known as spruelike enteropathy, can develop months to years after starting the drug.

The change resulted from research published in the July 2012 edition of Mayo Clinic Proceedings by a team of Mayo Clinic researchers. Gastroenterologist and study author Joseph Murray, M.D., says, “The FDA has done the right thing and their warning will bring this to the notice of doctors. We are still seeing new cases where the doctor was not aware of the problem.”

Click here for news release

Journalists: Sound bites with Dr. Murray are available in the downloads. To interview Dr. Murray please contact Brian Kilen at 507-284-5005 or newsbureau@mayo.edu.